Avience Biomedicals SME
Listing performance
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Grey market premium
Unofficial and indicative — not a forecast
Day-wise premium · 7 observations
| Date | GMP | % | Sauda | Est. listing | Gain / lot |
|---|---|---|---|---|---|
| 25 Jun 2026 | ₹145 | +69.71% | ₹66,100 | ₹353 | ₹87,000 |
| 24 Jun 2026 | ₹145 | +69.71% | ₹66,100 | ₹353 | ₹87,000 |
| 23 Jun 2026 | ₹95 | +45.67% | ₹43,300 | ₹303 | ₹57,000 |
| 22 Jun 2026 | ₹72 | +34.62% | ₹32,800 | ₹280 | ₹43,200 |
| 21 Jun 2026 | ₹70 | +33.65% | ₹31,900 | ₹278 | ₹42,000 |
| 20 Jun 2026 | ₹85 | +40.87% | ₹38,800 | ₹293 | ₹51,000 |
| 19 Jun 2026 | ₹85 | +40.87% | ₹38,800 | ₹293 | ₹51,000 |
Gain per lot assumes the premium holds to listing and that the application is allotted — allotment in an oversubscribed issue is a lottery, so it is indicative, not expected. Sauda is the rate paid for a submitted application itself.
Issue details
- IPO date
- 18 Jun 2026 – 22 Jun 2026
- Listing date
- 25 Jun 2026
- Face value
- ₹10 per share
- Price band
- ₹208
- Issue price
- ₹208 per share
- Lot size
- 600 shares
- Issue type
- Book Building issue
- Listing at
- NSE SME
- Total issue size
- ₹30.24 Cr
- Market cap at offer price
- ₹114 Cr
- Promoter holding
- 87.89% → 64.59% pre-issue → post-issue
- ISIN
- INE0V9I01017
- Registrar
- Skyline Financial Services Pvt.Ltd.
- Lead managers
- Fintellectual Corporate Advisors Pvt.Ltd.
- Registered office
- C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 4,09,800 | — | — |
| Market maker | 82,200 | — | — |
Application size
Minimum 600 shares per lot, in multiples, at ₹208
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 600 | ₹1,24,800 |
| S-HNI (min) | 2 | 1,200 | ₹2,49,600 |
| S-HNI (max) | 8 | 4,800 | ₹9,98,400 |
| B-HNI (min) | 9 | 5,400 | ₹11,23,200 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Valuation and performance
Valuation at offer price
₹208 per share
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 17.94 | 12.56 |
| P/E (×) | 11.59 | 16.56 |
| Price to book (×) | 3.68 | — |
| Market cap | — | ₹114 Cr |
Key performance indicators
Latest reported period
- Return on net worth
- 49.89%
- ROCE
- 24.84%
- Debt / equity
- 0.97
- PAT margin
- 15.86%
- EBITDA margin
- 25.22%
- NAV per share
- ₹56.5
- Price to book
- 3.68
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Avience Biomedicals SME
Avience Biomedicals Limited (formerly Avience Biomedicals Private Limited) was incorporated on December 23, 2019 in Delhi and converted into a public limited company on September 3, 2024. Recognized under the Make in India Mission, it commenced operations by producing essential diagnostic kits such as Viral Transport Media (VTM), Covid, HIV, HBsAG, Malaria and Dengue tests, and has since expanded into a comprehensive line of medical devices including serology products, biochemistry analysers and biochemistry reagents. The company operates from a leasehold manufacturing facility at G-1, Sector-11, Noida, Uttar Pradesh (approx. 3,700 sq ft) and is setting up a new manufacturing unit at Plot No. 70, Sector 28, Medical Device Park, YEIDA, Gautam Buddha Nagar; it is an ISO 9001:2016, ISO 13485, ZED MSME Gold and GMP certified organization whose production adheres to norms established by the Central Drugs Standard Control Organization (CDSCO). It earns money from two streams: trading/distribution of third-party medical equipment, surgical instruments, consumables and laboratory reagents (historically the largest contributor, 68.44%-83.81% of standalone revenue from operations across FY23-9MFY26) and in-house manufacturing of IVD rapid tests, reagents & consumables, analysers/instruments and culture media (16.19%-30.70%), plus minor services income. Products are sold B2B/B2C/B2G through direct sales and a dealer/distributor network (78 dealers as of January 31, 2026) to pathology labs, microbiology labs, hospitals and research centres nationwide, with exports to over six countries including Dubai, Ethiopia, Ghana, Somalia, Nepal and Zambia. In August 2023, via a share purchase agreement dated August 8, 2023, it acquired D R Meditech Surgical and Diagnostics (India) Private Limited (99.99% holding), its wholly owned subsidiary. Restated standalone FY2025 revenue from operations was ₹2,888.95 lakhs with PAT of ₹513.50 lakhs; consolidated FY2025 total revenue was ₹4,596.74 lakhs with PAT of ₹723.18 lakhs.
Company Analysis
from DRHPAvience Biomedicals Limited is a medical consumables company that manufactures and trades in-vitro diagnostic (IVD) rapid test kits, reagents, biochemistry analysers and other medical devices for pathology labs, hospitals and research centres in India and overseas.
Avience Biomedicals Limited (formerly Avience Biomedicals Private Limited) was incorporated on December 23, 2019 in Delhi and converted into a public limited company on September 3, 2024. Recognized under the Make in India Mission, it commenced operations by producing essential diagnostic kits such as Viral Transport Media (VTM), Covid, HIV, HBsAG, Malaria and Dengue tests, and has since expanded into a comprehensive line of medical devices including serology products, biochemistry analysers and biochemistry reagents. The company operates from a leasehold manufacturing facility at G-1, Sector-11, Noida, Uttar Pradesh (approx. 3,700 sq ft) and is setting up a new manufacturing unit at Plot No. 70, Sector 28, Medical Device Park, YEIDA, Gautam Buddha Nagar; it is an ISO 9001:2016, ISO 13485, ZED MSME Gold and GMP certified organization whose production adheres to norms established by the Central Drugs Standard Control Organization (CDSCO). It earns money from two streams: trading/distribution of third-party medical equipment, surgical instruments, consumables and laboratory reagents (historically the largest contributor, 68.44%-83.81% of standalone revenue from operations across FY23-9MFY26) and in-house manufacturing of IVD rapid tests, reagents & consumables, analysers/instruments and culture media (16.19%-30.70%), plus minor services income. Products are sold B2B/B2C/B2G through direct sales and a dealer/distributor network (78 dealers as of January 31, 2026) to pathology labs, microbiology labs, hospitals and research centres nationwide, with exports to over six countries including Dubai, Ethiopia, Ghana, Somalia, Nepal and Zambia. In August 2023, via a share purchase agreement dated August 8, 2023, it acquired D R Meditech Surgical and Diagnostics (India) Private Limited (99.99% holding), its wholly owned subsidiary. Restated standalone FY2025 revenue from operations was ₹2,888.95 lakhs with PAT of ₹513.50 lakhs; consolidated FY2025 total revenue was ₹4,596.74 lakhs with PAT of ₹723.18 lakhs.
Objects of the Issue
- Part-financing capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh ₹1,404.53 Lakhs p.24
- Funding the working capital requirement of the Company ₹825.00 Lakhs p.24
- General corporate purposes ₹397.21 Lakhs p.24
Issue Structure
- Total Issue
- Up to 14,53,800 Equity Shares of face value ₹10/- each at an Issue Price of ₹208 per Equity Share, aggregating up to ₹3,023.90 Lakhs (including a Market Maker Reservation Portion of 82,200 Equity Shares aggregating ₹170.98 Lakhs)
- Fresh Issue
- Up to 14,53,800 Equity Shares aggregating up to ₹3,023.90 Lakhs (the entire issue constitutes a fresh issue)
- Offer for Sale
- Nil
- Price Band
- Minimum price of ₹196 per Equity Share (Floor Price) and maximum price of ₹208 per Equity Share (Cap Price); Issue Price fixed at ₹208 per Equity Share
- Lot Size
- 600 Equity Shares and in multiples of 600 Equity Shares thereafter
- Face Value
- ₹10 per Equity Share
Business Model
Revenue comes from (1) trading/distribution of third-party medical equipment, surgical instruments, consumables, laboratory reagents and diagnostic equipment — the largest stream (68.44% of standalone revenue from operations for the period ended January 31, 2026; 83.81% in FY23) — and (2) manufacturing and sale of its own IVD rapid test kits, reagents & other consumables, analysers/instruments and culture media (30.70% in 9MFY26), plus a small 'sale of services' income (0.86%). Sales are made directly and through a growing dealer/distributor network (50 dealers in FY23 rising to 78 by January 31, 2026) to pathology labs, microbiology labs, hospitals and research centres, partly via government tenders, and through exports to over six countries (Dubai, Ethiopia, Ghana, Somalia, Nepal, Zambia).
Business Segments
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Dharam Deo Choudhary | Promoter | 50.57% | 37.17% |
| Ram Nagina Choudhary | Promoter | 15.93% | 11.71% |
| Janardan Pal | Promoter | 10.43% | 7.66% |
| Deepa Choudhary | Promoter | 10.88% | 7.99% |
| Geeta Choudhary | Promoter Group | 0.02% | 0.02% |
| Arti Pal | Promoter Group | 0.02% | 0.02% |
| Kapil Deo Choudhary | Promoter Group | 0.02% | 0.02% |
Leadership
Auto-extracted from the company's DRHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official DRHP before relying on it.